泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.02.019

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 224-227.doi: 10.3969/j.issn.1672-5069.2021.02.019

泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究

聂柳, 彭罕鸣, 廖东亮

430000 武汉市华中科技大学同济医学院附属武汉儿童医院消化二内科(聂柳,彭罕鸣);
武汉市普仁医院肿瘤科(廖东亮)

收稿日期:2020-07-24 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 彭罕鸣,E-mail:yhl778@sina.com
作者简介:聂柳,女,39岁,大学本科,主治医师。研究方向:儿童肝病诊治。E-mail:Zgshyxvip@126.com
基金资助:
武汉市科技局科研计划项目(编号201806232)

Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis

Nie Liu, Peng Hanming, Liao Dongliang

Second Department of Gastroenterology,Children's Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology,Wuhan 430000,Hubei Province, China

Received:2020-07-24 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的观察应用泼尼松和硫唑嘌呤联合雄去氧胆酸治疗自身免疫性肝炎(AIH)患者的疗效及对血清补体C3和C4水平的影响。方法 2017年2月～2019年12月我院消化内科诊治的120例AIH患者被随机分为对照组60例和观察组60例,分别给予泼尼松和硫唑嘌呤治疗或两者联合熊去氧胆酸治疗,平均治疗21.4个月。采用免疫比浊法检测血清免疫球蛋白M(IgM)、IgG和IgA水平,采用散射比浊法检测血清补体C3和C4水平。结果在治疗结束时,观察组血清谷丙转氨酶(ALT)水平为(55.2±6.9)U/L,显著低于对照组【(91.2±12.8)U/L,P<0.05】,血清谷草转氨酶(AST)水平为(59.7±7.5)U/L,显著低于对照组【(101.5±13.5)U/L,P<0.05】,血清碱性磷酸酶(ALP)水平为(122.4±15.7)U/L,显著低于对照组【(138.9±15.2)U/L,P<0.05】,血清谷氨酰转肽酶(GGT)水平为(120.7±10.1)U/L,显著低于对照组【(161.5±20.7)U/L,P<0.05】;观察组血清补体C3水平为(0.6±0.1)g/L,显著低于对照组【(0.8±0.2)g/L,P＜0.05】,观察组血清补体C4水平为(0.1±0.1)g/L,显著低于对照组【(0.2±0.1)g/L,P＜0.05】;观察组血清IgG水平为(12.5±2.0)g/L,显著低于对照组【(20.4±2.7)g/L,P＜0.05】,观察组血清IgM水平为(2.7±0.9)g/L,显著低于对照组【(3.4±1.1)g/L,P＜0.05】。结论应用泼尼松龙和硫唑嘌呤联合熊去氧胆汁酸治疗AIH患者可有效降低血清C3和C4水平,改善机体的免疫功能紊乱,改善肝功能指标,近期疗效值得关注。

关键词: 自身免疫性肝炎, 熊去氧胆酸, 泼尼松, 硫唑嘌呤, 补体C3, 补体C4, 治疗

Abstract: Objective The aim of this study was to observe the efficacy of combination of ursodeoxycholic acid (UDCA) and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis (AIH).Methods 120 AIH patients were recruited in the Department of Gastroenterology in our hospital between February 2017 and December 2019, and were randomly divided into control and observation groups with 60 cases in each group. The patients in the control received prednisone and azathioprine, while those in the observation group received UDCA at base of prednisone and azathioprine therapy. The regimen lasted for 21 months. Serum complement 3 (C3), C4, as well as immunoglobulin were detected.Results At the end of the treatment, serum alanine aminotransferase level in the observation group was (55.2±6.9)U/L, significantly lower than 【(91.2±12.8)U/L, P<0.05】, serum aspartate aminotransferase level was (59.7±7.5)U/L, significantly lower than 【(101.5±13.5)U/L, P<0.05】, serum alkaline phosphatase level was (122.4±15.7)U/L, much lower than 【(138.9±15.2)U/L, P<0.05】, and serum glutamyl transpeptidase level was (120.7±10.1)U/L, significantly lower than 【(161.5±20.7)U/L, P<0.05】 in the control; serum C3 level in the observation was (0.6±0.1)g/L, significantly lower than 【(0.8±0.2)g/L,P＜0.05】, and serum C4 level was (0.1±0.1)g/L, significantly lower than 【(0.2±0.1)g/L, P＜0.05】 in the control; serum IgG level in the observation group was (12.5±2.0)g/L, significantly lower than 【(20.4±2.7)g/L, P＜0.05】, and serum IgM level was (2.7±0.9)g/L, significantly lower than 【(3.4±1.1)g/L, P＜0.05】 in the control.Conclusion The administration of ursodeoxycholic acid at base of prednisolone and azathioprine combination in the treatment of patients with AIH could effectively reduce serum C3 and C4 levels, improve immune functions and alleviate liver injury, which needs further investigation.

Key words: Autoimmune hepatitis, Ursodeoxycholic acid, Prednisone, Azathioprine, Complement C3, Complement C4, Therapy

聂柳, 彭罕鸣, 廖东亮. 泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 224-227.

Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.

参考文献

[1] Han HS , Ahn GR , Kim H, et al. Diffuse systemic sclerosis in a patient with primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: a case report. Ann Dermatol, 2020, 32(1):69.
[2] Giuseppe M, Nastasio S, Sciveres M. Steroid free treatment in autoimmune hepatitis: is azathioprine monotherapy truly a viable option to obtain remission. J Pediatr, 2019, 210(8):56-58.
[3] Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis. J Dig Dis, 2019, 20(7):331-337.
[4] Vespasiani-Gentilucci U, Rosina F, Pace-Palitti V, et al. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients inItaly. Scand J Gastroenterol, 2019, 54(10):1274-1282.
[5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 中华肝脏病杂志, 2016, 24(1):23-35.
[6] 邱德凯, 马雄. 自身免疫性肝病的诊断和治疗. 中华肝脏病杂志, 2005, 13(1):50-51.
[7] Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res , 2019, 2019:107-113.
[8] Adiga A, Nugent K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis). Am J Med Sci, 2017. 353(4):329-335.
[9] Persaud A, Ahmed A, Kakked G, et al. Association of autoimmune hepatitis and cardiovascular disease. Dig Liver Dis, 2019, 51(11):1604-1609.
[10] Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: current and future therapeutic options.Liver Int, 2019, 39(6):1002-1013.
[11] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int, 2018. 38(1):15-22.
[12] Chang C, Tanaka A, Bowlus C,et al. The use of biologics in the treatment of autoimmune liver disease. Expert Opin Inv Drug, 2020, 29(10): 385-398.
[13] Li WY, Yang XS, Wang YC. Glucocorticoids in combination with ursodesoxycholic acid in the treatment of autoimmune hepatitis. J Biol Regul Homeost Agents, 2018, 32(2):307-311.
[14] Pape SC, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019, 7(9): 1156-1163.
[15] Minaga K, Watanabe T, Chung H, et al. Autoimmune hepatitis andIgG4-related disease. World J Gastroenterol, 2019, 25(19): 2308-2314.
[16] Wijaya I. Therole of ursodeoxycholic acid in acute viral hepatitis: an evidence-based case report. Acta Med Indones, 2015, 47(4):352-357.
[17] Trauner M, Nevens F, Shiffman ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453.
[18] Montano-Loza AJ, Bhanji RA, Wasilenko S, et al. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther, 2017, 45(4):485-500.
[19] Lammert C. Genetic and environmental risk factors for autoimmune hepatitis. Clin Liver Dis (Hoboken), 2019, 14(1):29-32.
[20] Kerkar N, Chan A. Autoimmune hepatitis, sclerosing cholangitis, and autoimmune sclerosing cholangitis or overlap syndrome. Clin Liver Dis, 2018, 22(4):689-702.
[21] Fan X, Zhu YJ, Men R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: a real-world study. Can J Gastroenterol Hepatol, 2018, 2018: 1965492.

泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究

Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁平戈, 陈文雯. 非酒精性脂肪性肝炎新药研发临床思考[J]. 实用肝脏病杂志, 2021, 24(3): 305-307.
[2]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[3]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[4]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[5]	裴旭东, 张晓虎, 褚桂克, 李延玲, 赵萍, 王立坤, 陈新菊. 消脂祛浊方治疗合并肥胖的痰湿型非酒精性单纯性脂肪肝患者临床效果初步研究[J]. 实用肝脏病杂志, 2021, 24(3): 355-358.
[6]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[7]	王云强, 王丽萍, 黄冬梅, 王艳彬, 刘晓杰, 李明宇, 赵欣宇. 经颈静脉肝内门体静脉分流术治疗乙型肝炎肝硬化门脉高压症患者疗效和血流动力学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 399-402.
[8]	伍畅, 张远安, 彭春芬. 内镜下套扎术后应用卡维地洛治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(3): 403-406.
[9]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.
[10]	冯浩, 吕海涛, 王子伟, 吴娟. 一步法和分步法治疗胆囊结石合并胆总管结石患者疗效及并发症分析[J]. 实用肝脏病杂志, 2021, 24(3): 435-438.
[11]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[12]	张鑫赫, 田昊宇, 李异玲. 原发性胆汁性胆管炎治疗现状[J]. 实用肝脏病杂志, 2021, 24(3): 453-456.
[13]	郭丽, 宋元宗. Alagille综合征患儿临床治疗管理[J]. 实用肝脏病杂志, 2021, 24(2): 160-163.
[14]	贺宇峰, 钟晓妮, 黄建溶, 赖思奇. 替诺福韦酯与恩替卡韦治疗慢性乙型肝炎患者疗效和血清成纤维细胞生长因子-23水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 200-203.
[15]	刘云华, 笪荣峰, 徐湖波, 江应平, 谢华平. 多烯磷脂酰胆碱治疗抗结核药物所致肝损伤患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 228-231.